Novel Vaccines - 概要

Ashley J. Birkett, Ph.D., Director, Preclinical Research & Development, The PATH Malaria Vaccine Initiative

konstantim Chumakov Konstantin Chumakov, Ph.D., Chief, Laboratory of Method Development, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration (FDA)

Heather Davis, Ph.D., Senior Vice President, Vaccines Research Site Head, Ottawa Research Laboratories, Coley Pharmaceutical Group, a Pfizer company

Ofer Levy, M.D., Ph.D., Staff Physician, Infectious Diseases and Principal Investigator, Harvard Medical School/Children’s Hospital Boston

Jan Vinje Jan Vinjé, Ph.D., Head, National Calicivirus Laboratory, Gastroenteritis & Respiratory Viruses Laboratory Branch, Division of Viral Diseases (DVD), National Center for Immunizations and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention (CDC)

Nicholas I. Obiri, Ph.D., Senior Regulatory
Affairs Specialist, Office of Regulatory Affairs, National Institute of Allergy and Infectious Diseases (NIAID), NIH

Scientific Advisors
Carol Belzer, Ph.D., Microbiology, Biotechnology
Immunology & Diagnostics, US Dept of Agriculture
William Egan, Ph.D., Executive Director, PharmaNet Consulting
Michael Dekleva, Ph.D., Director, Worldwide Regulatory Group Vaccines, Merck & Co
Gregory M. Glenn, M.D., Chief Scientific Officer, IOMAI Corporation
Jamie K. Scott, Ph.D., Professor & Canada Research Chair in Molecular Immunity, Molecular Biology & Biochemistry, Simon Fraser UniversityMichael Dekleva, Ph.D., Director, Worldwide Regulatory Group Vaccines, Merck & Co

Selected Papers:
A djuvants: Breathing New Life Into Vaccines
An interview with Nathalie Garcon, Pharm.D., Ph.D., Vice President,
Research and North America R&D, Guano SmithKline Biologicals,
by Malorye Allison, contributing editor, PharmaWeek

A Novel Strategy to Mimic Discontinuous Protective Epitopes Using a Synthetic Scaffold
Robert Liskamp, Ph.D., Professor, Pharmaceutical Sciences and Chemistry, Utrecht University

To post questions to any of the authors, or to submit a paper or comment, please email: vaccines@healthtech.com

概要 | 第1日目 | 第2日目 | 第3日目





メニュー概要 Novel Vaccines Advances In Cancer Vaccines Clinical Risk Management For Vaccines ホテルとトラベルスポンサー/出展カタログ(英語版PDF) ポスターお問い合わせお申し込み Sponsoring Publications Corporate Sponsor:	Novel Vaccines - 概要概要 \| 第1日目 \| 第2日目 \| 第3日目 Ashley J. Birkett, Ph.D., Director, Preclinical Research & Development, The PATH Malaria Vaccine Initiative Konstantin Chumakov, Ph.D., Chief, Laboratory of Method Development, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration (FDA) Heather Davis, Ph.D., Senior Vice President, Vaccines Research Site Head, Ottawa Research Laboratories, Coley Pharmaceutical Group, a Pfizer company Ofer Levy, M.D., Ph.D., Staff Physician, Infectious Diseases and Principal Investigator, Harvard Medical School/Children’s Hospital Boston Jan Vinjé, Ph.D., Head, National Calicivirus Laboratory, Gastroenteritis & Respiratory Viruses Laboratory Branch, Division of Viral Diseases (DVD), National Center for Immunizations and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention (CDC) Nicholas I. Obiri, Ph.D., Senior Regulatory Affairs Specialist, Office of Regulatory Affairs, National Institute of Allergy and Infectious Diseases (NIAID), NIH Scientific Advisors Carol Belzer, Ph.D., Microbiology, Biotechnology Immunology & Diagnostics, US Dept of Agriculture William Egan, Ph.D., Executive Director, PharmaNet Consulting Michael Dekleva, Ph.D., Director, Worldwide Regulatory Group Vaccines, Merck & Co Gregory M. Glenn, M.D., Chief Scientific Officer, IOMAI Corporation Jamie K. Scott, Ph.D., Professor & Canada Research Chair in Molecular Immunity, Molecular Biology & Biochemistry, Simon Fraser UniversityMichael Dekleva, Ph.D., Director, Worldwide Regulatory Group Vaccines, Merck & Co Selected Papers: A djuvants: Breathing New Life Into Vaccines An interview with Nathalie Garcon, Pharm.D., Ph.D., Vice President, Research and North America R&D, Guano SmithKline Biologicals, by Malorye Allison, contributing editor, PharmaWeek A Novel Strategy to Mimic Discontinuous Protective Epitopes Using a Synthetic Scaffold Robert Liskamp, Ph.D., Professor, Pharmaceutical Sciences and Chemistry, Utrecht University To post questions to any of the authors, or to submit a paper or comment, please email: vaccines@healthtech.com 概要 \| 第1日目 \| 第2日目 \| 第3日目	言語選択市場調査報告書 CHIの一部門により発行される調査報告書一覧です
日本語公式サイト運営：Cambridge Healthtech Institute 代理店株式会社グローバルインフォメーション

メニュー

Sponsoring Publications

Corporate Sponsor:

Novel Vaccines - 概要

言語選択

市場調査報告書